Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

Biologic or biosimilar: what are prescribers thinking?

Biosimilars are raising their competitive game, but are physicians convinced? And what do they see as the best next moves for biologics?

- PMLiVE

Accelerating innovation

Ipsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach

How to provide affiliate-friendly content

To ensure that your core content gets used by affiliates, empowerment is key. Here are two simple strategies to achieve it.

Anthill Agency

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

- PMLiVE

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

Moves a step closer to the rheumatoid arthritis market

- PMLiVE

Damien McDevitt moves from GSK to Acadia Pharmaceuticals

Takes up position as SVP, corporate development at the US biopharma firm

Webinar: Portfolio tracking for success

Thursday 18th January 2018 11:00 EST / 16:00 GMT / 17:00 CEST

Inizio

20 questions: Round-up video

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions throughout the year - this month we have created a final round-up video showcasing some...

Inizio

Marketing excellence starts with benchmarking

Uncovering marketing strengths and weaknesses

- PMLiVE

Shire suffers pipeline failure as takeover speculation builds

Several big pharma companies are reportedly considering bids

- PMLiVE

Spark’s Luxturna becomes US’s first approved gene therapy

FDA says its move 'reinforces the potential of this breakthrough'

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links